PainReform Stock (NASDAQ:PRFX)
Previous Close
$0.85
52W Range
$0.61 - $6.65
50D Avg
$0.93
200D Avg
$1.50
Market Cap
$1.71M
Avg Vol (3M)
$319.12K
Beta
0.58
Div Yield
-
PRFX Company Profile
PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.